The yellow antibiotic chrysomycin, isolated in crystalline form in 1955, is found to consist of two closely related components, a major one, chrysomycin A, and a minor one, chrysomycin B. They differ only through the replacement of a vinyl group of chrysomycin A by methyl in chrysomycin B. The absorption spectrum of chrysomycin A is identical with that of the antitumor antibiotic toromycin (gilvocarcin V, 2064A), while that of chrysomycin B is similarly identical with the one of gilvocarcin M (2064B). The structures of these antibiotics (toromycin, the gilvocarcins, and 2064A and B) have been elucidated recently. Chrysomycins A and B thus contain the same chromophores as gilvocarcins V and M, respectively; comparison of 1H and 13C NMR spectra confirms this identity. The chrysomycins differ from these other antibiotics in the C-glycosidic side-chain, which is a methylpentose in the gilvocarcins, a 3,5-dimethylpentose in the chrysomycins.
The yellow, crystalline antibiotic chrysomycin was discovered in 1955 at the New York Botanical Garden by STRELITZ et al.1) during their studies of antibiotic substances active against bacteriophage; these studies had been undertaken in the hope that the antiphage activity might serve as a guide for action against viruses, particularly the poliomyelitis virus. 2) Some physical, chemical, and biological properties of chrysomycin were recorded by STRELITZ et al.1), including the highly characteristic electronic absorption spectrum. However, elementary analyses for C, H, and 0 did not lead to a consistent empirical formula for the N-free antibiotic.1) This, and the fact that the ratio of the extinction coefficients of the two major UV peaks varied from one sample to the other,1) suggests that the chrysomycin of these authors, although nicely crystalline, was not a homogeneous compound. The remarkably low toxicity on intraperitoneal application in mice, noted by STRELITZ et al., was subsequently confirmed by us.
* I wish to dedicate this paper to the memory of my late friend Dr . FRIEDA STRELITZ, New York Botanical Garden, whose tireless effort was mainly responsible for the isolation of chrysomycin and for the accumulation of the material which enabled the present study to be carried out. Additional interest in the chrysomycins, 1 and 2, was generated by the work') on antibiotics 2064A
(3) and 2064B (4), which were found to be highly active in the biochemical induction assay (BIA) screening test) for antitumor activity; this test is based on prophage induction. The 2064 antibiotics showed electronic absorption spectra very similar to that of chrysomycin. Like these antibiotics, chrysomycin proved active in the BIA assay.
Analysis by HPLC led to the ready separation, on an analytical scale, of non-acetylated 1 and 2, which were found to have electronic spectra completely identical with those of 3 and 4, respectively, but to differ from them in chromatographic behavior. The same technique also proved that one of the old samples of chrysomycin was almost pure 1 (~98%). High-resolution mass spectrometry and elementary analysis of this sample established the elementary formula C28H28O9 for 1. In the IR spectrum, a carbonyl band at 1710 cm-1 is prominent. The 1H NMR spectrum showed the presence of one pair each of ortho-and meta-oriented aromatic protons, one isolated aromatic proton, two different aromatic methoxyls, the vinyl group, one secondary and one tertiary non-aromatic C-methyl, several hydroxyls, and four non-aromatic protons. The 1"C NMR spectrum of 1 showed that the prominent IR band at 1710 cm-1 most probably is caused by a coumarin group.
Investigation of the minute amounts of chrysomycin B (2) available from the analytical HPLC showed completely analogous behavior. The mass-spectrometric fragmentation of 2 produced the same pattern as that of 1 but with mass values lower by 12, as expected from the replacement of vinyl by methyl.
Chrysomycin B is thus C27H28O9; this conclusion was confirmed by the high-resolution mass-measurement of the molecular peak of 2 present as contaminant in a sample of 1. The fragmentation patterns of 3 and 4, in turn, were analogous to those of 1 and 2, but produced ions of mass lower by 14; the empirical formulae of 3 and 4 are therefore C27H26O9 and C26H26O9, respectively. In view of the identity of the electronic spectra of the two pairs (1 and 3, 2 and 4), the structural difference must reside in the nonchromophoric parts of those molecules.
Because of the impossibility of securing additional supplies of the chrysomycins, it was decided to reserve the limited quantity of available material for further biological tests; more detailed chemical studies were thus not feasible. Recently, however, 3 and 4 were found to be identical, spectroscopically * This relationship between 1 and 2 , while uncommon, is not unprecedented among pairs of natural compounds; see, e.g., the pyrethrins and cinerins. Other analogous, if less closely related instances of occurrencesometimes co-occurrence -of pairs of compounds R-C2 and R-Cl, where C2 is ethyl rather than vinyl, can be found among the pyrromycinones and rhodomycinones.
and chromatographically, with the antitumor antibiotics toromycin or gilvocarcin V, and gilvocarcin M, for which the structures and relative configurations shown below have been established.'-"* Evidently, structures 3 and 4 contain all of the features revealed for 1 and 2 by the 1H and 13C NMR signals ascribable to the aromatic moieties of these compounds; this fact further confirms the identity of the chromophores in 1 and 3, and 2 and 4, respectively.
The problem of establishing the complete structure and relative configuration of chrysomycins A and B (1 and 2, respectively) thus reduced itself to the elucidation of the side-chain, identical in both compounds. It was solved through application of 111 and 13C NMR spectroscopy, which led to the structure and relative configuration shown below. These spectra are documented in Tables 1, 2 , and 3, and Fig. 1 . The methyl glycoside of a sugar virenose, apparently identical with, or antipodal to, the C-glycosidic moiety of 1 and 2, has been obtained8) through methanolysis of an antitumor antibiotic virenomycin.9) The structure of the aglycone moiety of virenomycin has not yet been published, but UV data
The numbering system for the chromophores of 1-4 is the one given for the gilvocarcins, (3) and (4), in reference 5. suggest that it may be related to 5 and 6. The structure and stereochemistry of methyl ~-n-virenoside have been confirmed recently by total synthesis.10) Comparison of the 1H NMR spectrum of the triacetate of 1 with the published spectrum of the diacetate of synthetic methyl ,8-n-virenoside shows close correspondence of the coupling constants, while the chemical shifts of 1 triacetate reflect the presence of the aromatic system. See Table 4 .
Molecular models of 1 triacetate indicate that the most probable conformations of the pyranose system place the sugar protons above the aromatic rings. As a consequence, the 2'-acetoxy group produces a signal at 1.19 ppm, 1.0 ppm above the one of the 4'-acetoxy group.
The in vivo antitumor activity of chrysomycin was determined in mice against P 388 lymphocytic leukemia under contracted accessory services in accordance with the National Cancer Institute guidelines for natural products.11) The sample tested contained 86 percent chrysomycin A and 14 percent chrysomycin B. Supply limitations confined the testing to a single dose, administered intraperitoneally 24 hours after inoculation with the leukemia cells. The drug was suspended in hydroxypropyl cellulose.
At 400 mg/kg chrysomycin produced an increase of the life span (ILS) of the treated mice of 54 %, while exhibiting no lethal toxicity. These data are very similar to those (ILS 57 %, LD50 > 1,000 mg/kg) reported12) for gilvocarcin V. The action of STRELITZ and FLON's chrysomycin against a number of bacteria, molds, and bacteriophages is discussed in reference 1. The biosynthesis of the chromophoric moieties of antibiotics 1 -4 presents an interesting problem.
As indicated in diagram 6, these structures are undoubtedly of polyketide origin, but they can hardly be formed completely by simple folding of one single acetate-malonate-derived carbon chain. A formation from two such chains would have a precedent e.g. in the cases of citromycetin13) and mollisin14,15,16) ; alternatively, these structures could be interpreted as arising from one chain (as is the case with the vast majority of polyketides of known biosynthetic origin), if the group R were a secondary additionan assumption which is plausible enough for R=CH3, but hardly for R = CH=CH2.
In the absence of experimental evidence, we prefer to assume formation of these structures by oxidative cleavage of a 1,2-benzanthraquinone precursor such as 7, with subsequent unexceptional changes:
decarboxylation to 8, reduction, lactonization, and O-methylation, as shown below:
Several microbial metabolites with the ring system of 7 are known; one of them, tetrangulol, 917), actually differs from 7, R=CH3, only through the absence of the 0-methyl and the C-glycosidic side-chain. Other compounds of this type" are tetrangomycin,l7 ochromycinol, rabelomycin, and aquayamycin (this last one a C-glycoside!).
It is striking that all these structures, including 1 -4, lack the oxygenated function in the marked (*) position of the ring system, which would be expected to be present on the basis of the polyketide origin.
A similar biosynthesis has been discussed", as one of several possibilities, for the antibiotic chartreusin, 10, whose structure20) bears an unmistakable resemblance to those of compounds 1-4.
(7) R = CH=CH2 or CH3 S = sugar side-chain (8) (6) (=1~4) (9) (10) Experimental Materials and Methods All the chrysomycin used had been isolated by STRELITZ and FLON1) during the initial work on this antibiotic. The material consisted of a number of small samples, all but one of which were found to be mixtures of much chrysomycin A (1) with varying smaller amounts of chrysomycin B (2). The one exceptional sample, shown by HPLC to consist of -98 % pure 1, served for the analytical and spectroscopic characterization of this compound.
NMR spectra (electron impact) were recorded on the JEOL FX-60 and NTC-360 instruments of the National Heart, Lung, and Blood Institute, with TMS as internal standard. IR spectra were taken in KBr pellets on a Beckman Model 4230 instrument. Melting points were taken on a Reichert hot-stage microscope; they are not corrected for stem exposure. High-resolution mass spectra were taken on an MS-2902 instrument.
Chrysomycin B (2) Only minute amounts of the pure compound have been obtained so far. The UV and visible spectrum of 2 agrees with the one of gilvocarcin M shown in Fig. 1 of reference 6 . The pattern of the massspectrometric fragmentation of 2 closely resembles that of 1, with the corresponding peaks occurring at The old sample (-90% A and 10% B, by HPLC), 4 mg, was dissolved in 1 ml pyridine, and acetic anhydride (1 ml) was added dropwise with stirring. The mixture was stirred at room temperature for 24 hours. It was next concentrated under reduced pressure, and the residue was taken up in CHCl3 (1 ml). The triacetates of 1 and 2 were separated on a C-18 Magnum 9 column (Whatman Inc.) with methanol -H2O -tetrahydrofuran (50: 35: 15) as mobile phase. The retention times were 17.5 minutes for the triacetate of chrysomycin A, and 14.5 for that of B. Mass spectrometry confirmed the presence of three acetyl groups. Table 3 ), and of the three 0-acetyl groups (o 1.20, 2.28, 2.42, s, 3H). The low o-value of one of these (also observed in tetraacetylgilvocarcin V6) and tetraacetyltoromycin5)) is undoubtedly caused by the influence of the aromatic chromophore; this circumstance localizes5) this particular acetoxy group on C-2'. Another species, S. anandii, was found by BALTTZ et al. 22 ) to produce 3 and 4, together with the new gilvocarcin E, in which the vinyl group of 3 is replaced by ethyl. It was observed22) that all three antibiotics elaborated by S. anandii have antimicrobial action, but that antitumor activity is restricted to gilvocarcin V (3).
VOL. XXXV NO. 9 THE JOURNAL OF ANTIBIOTICS
